L-TIL in Patients With Malignancy Resistance to Anti-PD-1 Therapy

  • STATUS
    Recruiting
  • participants needed
    30
  • sponsor
    Henan Cancer Hospital
Updated on 19 February 2024
cancer
measurable disease
blood pregnancy test

Summary

Safety and effectiveness of liquid tumor infiltrating lymphocytes in patients with advanced malignant tumors who have failed to anti-PD-1 therapy

Details
Condition Advanced Solid Tumor
Age 18years - 70years
Treatment liquid tumor infiltrating lymphocytes
Clinical Study IdentifierNCT04268108
SponsorHenan Cancer Hospital
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

Expected lifespan is over 3 months
malignant tumors diagnosed by pathological examination
Imaging examination is at advanced stage with at least one measurable lesion
Ineffective or resistant to previous anti-PD-1 therapy
ECOG score 0-2
Adequate organ function
No other serious diseases that conflict with this protocol
Women of childbearing age must check for a negative blood pregnancy test within 7 days, and subjects of childbearing age must use appropriate contraception during the test and within 3 months
witten informed consent from the patients

Exclusion Criteria

Severe infectious disease within 4 weeks before enrollment
Active hepatitis B or C virus or HIV infection
Severe autoimmune disease or immunodeficiency disease
Severe allergies
Severe mental disorder
Systematically used a large amount of glucocorticoids within 4 weeks before enrollment
With severe heart, liver, kidney insufficiency, diabetes and other diseases
Participation in other clinical studies in the past 3 months or having been treated with other gene products
Clear my responses

How to participate?

Step 1 Connect with a study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.